These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 8021603

  • 1. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Wilber BA, Docherty JJ.
    J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
    [Abstract] [Full Text] [Related]

  • 2. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
    Saijo M, Suzutani T, Mizuta K, Kurane I, Morikawa S.
    Arch Virol; 2008 Jul; 153(2):303-14. PubMed ID: 18066636
    [Abstract] [Full Text] [Related]

  • 3. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
    Balzarini J, De Clercq E, Verbruggen A, Ayusawa D, Shimizu K, Seno T.
    Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
    [Abstract] [Full Text] [Related]

  • 4. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
    Balzarini J, De Clercq E, Baumgartner H, Bodenteich M, Griengl H.
    Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
    [Abstract] [Full Text] [Related]

  • 5. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes.
    Schubert A, Gentner E, Bohn K, Schwarz M, Mertens T, Sauerbrei A.
    Antiviral Res; 2014 Jul; 107():16-22. PubMed ID: 24747042
    [Abstract] [Full Text] [Related]

  • 6. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
    Degrève B, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2001 Feb; 59(2):285-93. PubMed ID: 11160865
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
    Hamel W, Zirkel D, Mehdorn HM, Westphal M, Israel MA.
    Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
    [Abstract] [Full Text] [Related]

  • 15. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain.
    Saijo M, Suzutani T, De Clercq E, Niikura M, Maeda A, Morikawa S, Kurane I.
    Antiviral Res; 2002 Dec; 56(3):253-62. PubMed ID: 12406508
    [Abstract] [Full Text] [Related]

  • 16. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.
    Degrève B, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2000 Dec; 58(6):1326-32. PubMed ID: 11093770
    [Abstract] [Full Text] [Related]

  • 17. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.
    Field H, McMillan A, Darby G.
    J Infect Dis; 1981 Feb; 143(2):281-5. PubMed ID: 6260876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
    Suzuki M, Okuda T, Shiraki K.
    Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.